A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Emetogenic Chemotherapy in Adolescent Patients

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Emetogenic Chemotherapy in Adolescent Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Ondansetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Feb 2009 Results published in Current Contents.
    • 31 Jul 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
    • 27 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top